ORIC Pharmaceuticals, Inc. (ORIC)
ORIC Pharmaceuticals, Inc. (ORIC) is a healthcare company (biotechnology) based in the United States. The share price is $7.65, up 1.73% on the day, which values the company at $792.94M. Price as of 17 Nov 2026, 17:26 UTC, from Yahoo Finance.
Key facts
- Share price
- $7.65+1.73% today
- Market value
- $792.94M
- 200-week average
- $9.2017% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
ORIC Pharmaceuticals, Inc. in more detail
ORIC trades at -4.4× next year's expected earnings. It sits 17% below its 200-week average of $9.20.
In its favour: More cash than debt. Worth checking: Share count keeps rising.
2 of the superinvestors tracked here hold ORIC, including Takis Sparaggis (0.2% of the portfolio), Andreas Halvorsen (0.2% of the portfolio).
Superinvestors holding ORIC
2 of the investors tracked here report a position in their latest 13F filing.
- Takis Sparaggis Alkeon Capital Management0.18% of portfolio · $43.6M · trimmed · Q3 2026
- Andreas Halvorsen Viking Global Investors0.16% of portfolio · $55.5M · trimmed · Q2 2026
ORIC Pharmaceuticals, Inc. (ORIC): questions and answers
What is ORIC Pharmaceuticals, Inc.'s market cap?
ORIC Pharmaceuticals, Inc. is valued at $792.94M at a share price of $7.65.
Is ORIC above its 200-week moving average?
No. ORIC is 16.8% below its 200-week average of $9.20. Long-term investors watch that line because strong companies rarely trade below it for long.
Does ORIC pay a dividend?
ORIC Pharmaceuticals, Inc. does not currently pay a regular dividend.
Which famous investors own ORIC?
In their latest quarterly filings, Takis Sparaggis (0.2% of the portfolio), Andreas Halvorsen (0.2% of the portfolio) hold ORIC. These filings are published up to 45 days after each quarter ends, so positions may have changed since.
When does ORIC Pharmaceuticals, Inc. report earnings next?
ORIC Pharmaceuticals, Inc.'s next earnings report is expected on November 16, 2026. The date comes from the market data feed and companies do move it.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “ORIC Pharmaceuticals, Inc. (ORIC) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/ORIC
Underlying data: Yahoo Finance; company filings with the SEC.